Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine as Conversion Therapy of Locally Advanced Colorectal Cancer - Trial NCT06405139
Access comprehensive clinical trial information for NCT06405139 through Pure Global AI's free database. This Phase 2 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Colorectal Cancer. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & Enrollment
Phase 2
May 06, 2024
Apr 30, 2027
Primary Outcome
Organ-sparing R0 Resection Rate
Summary
Neoadjuvant chemotherapy has gained acceptance in treating locally advanced breast cancer,
 esophageal cancer, gastric cancer, and rectal cancer. However, the role of neoadjuvant
 chemotherapy for locally advanced colon cancer is still in the exploratory stage. The
 objective of this study is to explore the efficacy and safety of nanoliposomal irinotecan and
 oxaliplatin combined with capecitabine as a novel conversion therapy for locally advanced
 colorectal cancer patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06405139
Non-Device Trial